(MedPage Today) — GLP-1 receptor agonists and SGLT2 inhibitors were associated with lower risks for liver-related events and hepatocellular carcinoma (HCC) in type 2 diabetes patients compared with other glucose-lowering therapies, a systematic…
Source link : https://www.medpagetoday.com/gastroenterology/generalhepatology/119651
Author :
Publish date : 2026-01-29 20:28:00
Copyright for syndicated content belongs to the linked Source.
